Global Drug Discovery Informatics Market is valued approximately USD 1.89 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 11.20% over the forecast period 2019-2026. Drug discovery informatics is a functional process performed by biotechnology and pharmaceutical companies that requires the generation of very large data and information. Through application of modern engineering and computational approaches the models are analyzed, visualized and simulated for pharmacological profiling. Further, rising R&D expenditure on pharmaceuticals along with the increasing government focus on drug discovery are some key forces, driving the growth of the drug discovery informatics market over the forecast period of 2019-2026. For instance: According to the U.K. government in 2016, drug development sector and continuous manufacturing would receive funds around USD 82.5 million from government and private sources as part of its new USD 188 million effort and ?Industry Strategy' to establish six key research hubs in UK to boost research and development activities related to drug discovery. As a result, the adoption of the drug discovery informatics would increase thereby, contributing towards the growth of the market. However, high pricing and set up cost of informatics software impede the growth of the global drug discover informatics market.
Major market player included in this report are:
Jubilant Life Sciences
IBM
Infosys
Thermo Fisher Scientific
Perkinelmer
Schrodinger
Dassault Syst?mes
Charles River Laboratories
GVK Biosciences
Boehringer Ingelheim GmbH
The regional analysis of global drug discovery informatics market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to well-established healthcare infrastructure along with the presence of various biotechnology and drug companies. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026 due to availability of low cost of human resources and manufacturing and availability of many qualified researchers. Also, the growth of the Asia-Pacific region is attributed owing to the ongoing drug development activities undertaken by government.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Function:
Sequencing & Target Data Analysis
Docking
Molecular Modelling
Libraries & Database Preparation
Other Functions
By Solution:
Software
Services
By End-User:
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROS)
Others End Users
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2016, 2017
Base year - 2018
Forecast period - 2019 to 2026
Target Audience of the Global Drug Discovery Informatics Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
